中华消化杂志
中華消化雜誌
중화소화잡지
Chinese Journal of Digestion
2010年
2期
87-89
,共3页
吴建新%张敏红%陈源文%葛文松%周韵斓%范建高
吳建新%張敏紅%陳源文%葛文鬆%週韻斕%範建高
오건신%장민홍%진원문%갈문송%주운란%범건고
溃疡性结肠炎%英夫利昔%肿瘤坏死因子-α%黏膜%伤口愈合
潰瘍性結腸炎%英伕利昔%腫瘤壞死因子-α%黏膜%傷口愈閤
궤양성결장염%영부리석%종류배사인자-α%점막%상구유합
Ulcerative colitis%Infliximab%Tumor necrosis factor-alpha%Mucous%Wound healing
目的 总结英夫利昔(IFX)治疗3例暴发型溃疡性结肠炎(FUC)的经验,供临床参考.方法 对明确诊断的3例FUC患者采用IFX治疗,剂量为5 mg/kg,0.9%氯化钠溶液稀释后在2 h内静脉滴注完毕.间隔0、2、6周用药,共3次.维持缓解予以柳氮磺胺吡啶(SASP)或益生菌制剂.以内镜和病理检查结果 为主要依据,复查黏膜愈合情况.结果 3例FUC患者在IFX给药后均实现完全缓解.停药后第8周,2例复查肠镜显示黏膜完全愈合,另1例因室性心动过速复发而猝死.随访至IFX停药后8个月余,2例患者仍无任何活动表现.结论 应用IFX治疗3例FUC实现完全诱导缓解,最终的疗效和安全性有待进一步临床实践予以证实.
目的 總結英伕利昔(IFX)治療3例暴髮型潰瘍性結腸炎(FUC)的經驗,供臨床參攷.方法 對明確診斷的3例FUC患者採用IFX治療,劑量為5 mg/kg,0.9%氯化鈉溶液稀釋後在2 h內靜脈滴註完畢.間隔0、2、6週用藥,共3次.維持緩解予以柳氮磺胺吡啶(SASP)或益生菌製劑.以內鏡和病理檢查結果 為主要依據,複查黏膜愈閤情況.結果 3例FUC患者在IFX給藥後均實現完全緩解.停藥後第8週,2例複查腸鏡顯示黏膜完全愈閤,另1例因室性心動過速複髮而猝死.隨訪至IFX停藥後8箇月餘,2例患者仍無任何活動錶現.結論 應用IFX治療3例FUC實現完全誘導緩解,最終的療效和安全性有待進一步臨床實踐予以證實.
목적 총결영부리석(IFX)치료3례폭발형궤양성결장염(FUC)적경험,공림상삼고.방법 대명학진단적3례FUC환자채용IFX치료,제량위5 mg/kg,0.9%록화납용액희석후재2 h내정맥적주완필.간격0、2、6주용약,공3차.유지완해여이류담광알필정(SASP)혹익생균제제.이내경화병리검사결과 위주요의거,복사점막유합정황.결과 3례FUC환자재IFX급약후균실현완전완해.정약후제8주,2례복사장경현시점막완전유합,령1례인실성심동과속복발이졸사.수방지IFX정약후8개월여,2례환자잉무임하활동표현.결론 응용IFX치료3례FUC실현완전유도완해,최종적료효화안전성유대진일보림상실천여이증실.
Objective To report three cases of fulminant ulcerative colitis (FUC) treated with infliximab (IFX) and the positive result for clinical purpose. Methods Three patients with FUC were infused with IFX (5 mg/kg) at interval of 0, 2, 6 wk. Sulfasalazine or probiotics was used for the maintanance of remission. The mucosal healing was evaluated by endoscopy and patholoic examination. Results Complete remission was found in 3 patients with FUC. Eight weeks after IFX withdraw, complete remission was found in two of three cases demonstrated by endoscopy, except for one case died from refractory ventricular tachycardia. The remaing 2 cases showed no active manifestation during 8 months' follow-up. Conclusion IFX therapy results in complete remission in 3 cases with FUC. However, further randomized control study is warranted for concrete evaluation on salty and application clinically.